Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon (Nasdaq: PLRZ) has announced positive preclinical results for its PL-14 Allergy Blocker, demonstrating successful intranasal delivery in a collaborative study with the University of Parma. The study showed over 60% deposition of the product in the nasal vestibule, the critical first point of contact for airborne allergens.
The research validates the company's proprietary Capture & Contain (C&C) platform, supporting its mechanism of action as a physical barrier against allergens. The global allergen blocker market, valued at $0.14 billion in 2024, is projected to reach $0.21 billion by 2033, growing at a 4.4% CAGR. The company plans to advance toward clinical trials following these encouraging preclinical results.
Polyrizon (Nasdaq: PLRZ) ha annunciato risultati preclinici positivi per il suo PL-14 Allergy Blocker, dimostrando una somministrazione intranasale efficace in uno studio collaborativo con l'Università di Parma. Lo studio ha evidenziato una deposizione superiore al 60% del prodotto nel vestibolo nasale, il primo punto di contatto cruciale per gli allergeni trasportati dall'aria.
La ricerca conferma la validità della piattaforma proprietaria Capture & Contain (C&C) dell'azienda, che supporta il suo meccanismo d'azione come barriera fisica contro gli allergeni. Il mercato globale degli allergeni, valutato 0,14 miliardi di dollari nel 2024, è previsto crescere fino a 0,21 miliardi di dollari entro il 2033, con un tasso di crescita annuo composto del 4,4%. La società intende procedere verso le sperimentazioni cliniche dopo questi incoraggianti risultati preclinici.
Polyrizon (Nasdaq: PLRZ) ha anunciado resultados preclínicos positivos para su PL-14 Allergy Blocker, demostrando una administración intranasal exitosa en un estudio colaborativo con la Universidad de Parma. El estudio mostró una deposición superior al 60% del producto en el vestíbulo nasal, el primer punto crítico de contacto para los alérgenos en el aire.
La investigación valida la plataforma propietaria Capture & Contain (C&C) de la compañía, respaldando su mecanismo de acción como una barrera física contra los alérgenos. El mercado global de bloqueadores de alérgenos, valorado en 0,14 mil millones de dólares en 2024, se proyecta que alcance 0,21 mil millones de dólares para 2033, creciendo a una tasa compuesta anual del 4,4%. La empresa planea avanzar hacia ensayos clínicos tras estos alentadores resultados preclínicos.
폴리라이즌 (Nasdaq: PLRZ)은 PL-14 알레르기 차단제에 대한 긍정적인 전임상 결과를 발표했으며, 파르마 대학교와의 공동 연구에서 비강 내 투여가 성공적임을 입증했습니다. 연구 결과는 공기 중 알레르겐과 처음 접촉하는 중요한 부위인 비강 입구에 60% 이상의 제품 침착을 보여주었습니다.
이 연구는 회사의 독자적인 Capture & Contain (C&C) 플랫폼을 검증하며, 알레르겐에 대한 물리적 장벽으로서의 작용 메커니즘을 뒷받침합니다. 2024년 1억 4천만 달러로 평가된 전 세계 알레르겐 차단제 시장은 2033년까지 2억 1천만 달러에 이를 것으로 예상되며, 연평균 성장률은 4.4%입니다. 회사는 이러한 고무적인 전임상 결과를 바탕으로 임상 시험 단계로 나아갈 계획입니다.
Polyrizon (Nasdaq : PLRZ) a annoncé des résultats précliniques positifs pour son PL-14 Allergy Blocker, démontrant une administration intranasale réussie dans une étude collaborative avec l'Université de Parme. L'étude a montré une déposition de plus de 60% du produit dans le vestibule nasal, le premier point de contact crucial pour les allergènes aéroportés.
La recherche valide la plateforme propriétaire Capture & Contain (C&C) de l'entreprise, soutenant son mécanisme d'action en tant que barrière physique contre les allergènes. Le marché mondial des bloqueurs d'allergènes, évalué à 0,14 milliard de dollars en 2024, devrait atteindre 0,21 milliard de dollars d'ici 2033, avec un taux de croissance annuel moyen de 4,4%. L'entreprise prévoit d'avancer vers des essais cliniques suite à ces résultats précliniques encourageants.
Polyrizon (Nasdaq: PLRZ) hat positive präklinische Ergebnisse für seinen PL-14 Allergy Blocker bekannt gegeben und in einer gemeinsamen Studie mit der Universität Parma eine erfolgreiche intranasale Verabreichung nachgewiesen. Die Studie zeigte eine Deposition von über 60% des Produkts im Nasenvorhof, dem entscheidenden ersten Kontaktpunkt für luftgetragene Allergene.
Die Forschung bestätigt die firmeneigene Capture & Contain (C&C)-Plattform und unterstützt deren Wirkmechanismus als physikalische Barriere gegen Allergene. Der globale Markt für Allergenblocker, der im Jahr 2024 mit 0,14 Milliarden US-Dollar bewertet wird, soll bis 2033 auf 0,21 Milliarden US-Dollar anwachsen und mit einer jährlichen Wachstumsrate von 4,4% wachsen. Das Unternehmen plant, nach diesen vielversprechenden präklinischen Ergebnissen mit klinischen Studien fortzufahren.
- Achieved over 60% deposition in the nasal vestibule, demonstrating effective targeted delivery
- Product showed favorable sprayability and coverage for self-administration
- Addresses growing allergen blocker market projected to reach $0.21B by 2033
- Still in preclinical stage, requiring further validation and clinical trials
- Entering a competitive market with modest 4.4% CAGR growth rate
Insights
Polyrizon's PL-14 shows promising preclinical results with 60%+ nasal vestibule deposition, advancing its potential in the growing allergen blocker market.
Polyrizon's preclinical study results for its PL-14 Allergy Blocker represent a significant technical milestone in the company's development pipeline. The study demonstrated that PL-14 achieved over 60% deposition in the nasal vestibule, which is critical for the product's mechanism of action as a physical barrier against allergens.
The technical achievement here is noteworthy because targeted delivery to the nasal vestibule—the first area of contact for airborne allergens—is precisely what's needed for the product's "Capture & Contain" approach to work effectively. By forming a protective hydrogel barrier at the entry point of allergens, PL-14 aims to prevent allergic reactions before they begin, rather than treating symptoms after they've started.
From a market perspective, Polyrizon is positioning itself in the allergen blocker market valued at
The collaboration with the University of Parma and specifically Professor Fabio Sonvico adds credibility to these findings. The use of a validated silicone-based human nasal cast model with fluorescein-labeled imaging represents a standard approach for evaluating intranasal drug delivery before moving to human trials.
This announcement indicates progression toward clinical trials, though the company remains in the preclinical validation phase. For investors, this represents forward momentum in Polyrizon's development pipeline, though considerable development steps remain before commercialization could be achieved.
Ra’anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product’s potential as a barrier-forming treatment for allergic rhinitis.
The evaluation was led by Professor Fabio Sonvico from the Department of Food and Drug at the University of Parma, a leading authority in intranasal and pulmonary drug delivery and a member of Polyrizon’s Scientific Advisory Board. Using a validated silicone-based human nasal cast and fluorescein-labeled imaging, the study assessed the spray deposition profile of PL-14 when administered under clinically relevant conditions.
The results revealed that the PL-14 formulation achieved over
“We believe that the ability of our C&C platform to deliver a high concentration of hydrogel barrier to the vestibular region of the nose is a significant step forward,” said Tomer Izraeli, CEO of Polyrizon. “These results support the core principle behind our blocker products—to form a protective layer at the point of allergen entry and prevent the initiation of allergic reactions.”
According to Business Research Insights, the global allergen blocker market size was valued at USD 0.14 billion in 2024 and is expected to reach USD 0.21 billion by 2033, exhibiting a CAGR of
PL-14’s performance in this nasal cast model highlights its potential to become a frontline preventive treatment for allergic rhinitis. The hydrogel formulation also maintained favorable sprayability and coverage under standard administration angles, demonstrating its practicality for self-administration.
Polyrizon plans to continue preclinical validation and advance toward clinical trials as part of the development path for the C&C platform.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the PL-14 Allergy Blocker’s potential as a barrier-forming and frontline preventive treatment for allergic rhinitis, the expected growth of the global allergen blocker market and the Company’s continued preclinical validation and advancement toward clinical trials as part of the development path for the C&C platform. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ
What were the key findings of Polyrizon's (PLRZ) PL-14 Allergy Blocker study?
How does Polyrizon's PL-14 Allergy Blocker work?
What is the market potential for Polyrizon's allergy blocker?
What are the next steps for Polyrizon's PL-14 development?
Who conducted the study for Polyrizon's PL-14 Allergy Blocker?
